PPT-Buprenorphine in Medication Assisted

Treatment MAT Problem or Solution Quintin Thomas Chipley MA MD PhD a nd Greg Jones MD ABFM ABAM MRO Prepared for CAPTASA 2016 DISCLOSURES Neither presenter has any financial interest in any mode of treatment as discussed in this presentation. WHAT WORKS?. SHELLEY ASKEW FLOYD, MS. DIRECTOR OF PHARMACOTHERAPY SERVICES. PYRAMID HEALTHCARE, INC.. 1. OBJECTIVES:. 1. . Understanding the importance of medication assistance treatment(MAT) in a . Mark Stringer, Director. Missouri Divisions of Alcohol and Drug Abuse & Comprehensive Psychiatric Services. NASADAD Annual Meeting. Indianapolis, IN. June 8, 2011. Medication Assisted Treatment Timeline. John Arthur Muenz, Jr., M.D., FAAPM&R, FABAM, FAAFP. Family Care Partners. jmuenz@familycarepartners.com. Disclosure. I have no actual or potential conflict of interest in relation to this . program/presentation.. Michael Palladini, RPh MBA CAC. info@drugsofabuse.net. “BUNAVAIL . is the first and only FDA-approved buccal film formulation of . buprenorphine. and naloxone and will compete in the $1.7 billion and growing U.S. opioid dependence market. Presented by:. NJATOD Officers. Barbara . Schlichting. , NJATOD Secretary, Somerset Treatment Services . Christie . Hanvey. , NJATOD Vice President, Spectrum Healthcare Center. . Maiysha. Ware, NJATOD President, The . Mark Stringer, Director. Missouri Divisions of Alcohol and Drug Abuse & Comprehensive Psychiatric Services. NASADAD Annual Meeting. Indianapolis, IN. June 8, 2011. Medication Assisted Treatment Timeline. Opioid Use Disorder. Evidence-based Antidote . Prescription Drug & Heroin Crisis. John A. Peterson, MD. Past President-Illinois Society of Addiction Medicine. American Board of Internal Medicine. Some Best practices with medication assisted treatment Michele Flowers McCarthy, LPCC-S Director of Program Development Center for Behavioral Health Special thanks to Michele McCarthy Director of Program Development Medication Assisted Treatment For Opioid Use Disorders Shannon Allen, MD Jade Wellness Center July 19, 2018 Rates of Relapse in Opioid Use Disorders are High Benefits of Medication Assisted Treatments Diana Deister, MS, MD. Child and Adolescent Psychiatrist. Adolescent Substance Use and Addictions Program. Division of Developmental Medicine. Boston Children’s Hospital. October 24. th. , . 2017. Disclosure. Brian Grahan, MD, PhD. Addiction Medicine / Internal Medicine. 6/7/2018. Disclosures. This educational initiative is funded by a grant from the Minnesota Department of Human Services. I have no financial interests to disclose. . Trish Mashburn, PharmD. April 7th. , . 2022. Course Information. Presentation is sponsored by . the North Carolina Association of Pharmacists (. NCAP). . This live course has been adapted from the following online training module: . Breaking the Stigma. Christie Simons, MAMFT, LPCA, LCAS-A. Director of Counselor Services, Belmont Abbey College . McLeod Addictive Disease Center . Medication-Assisted Treatment. Introduction . Common Myths?. Michael Dulitz, MPH, NRP. Opioid Response Project Coordinator. Foundation. Addiction is a . chronic relapsing brain disease . characterized by compulsive use of a substance despite negative consequences.